These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 22503022

  • 1. The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression.
    Ng E, Woo HH, Turner S, Leong E, Jackson M, Spry N.
    J Urol; 2012 Jun; 187(6):2162-6. PubMed ID: 22503022
    [Abstract] [Full Text] [Related]

  • 2. Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?
    Mottet N, Lucas C, Sene E, Avances C, Maubach L, Wolff JM.
    Urol Int; 2005 Jun; 75(3):204-8. PubMed ID: 16215305
    [Abstract] [Full Text] [Related]

  • 3. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer.
    Spry NA, Kristjanson L, Hooton B, Hayden L, Neerhut G, Gurney H, Corica T, Korbel E, Weinstein S, McCaul K.
    Eur J Cancer; 2006 May; 42(8):1083-92. PubMed ID: 16632343
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ.
    Eur Urol; 1999 May; 35 Suppl 1():32-6. PubMed ID: 10081701
    [Abstract] [Full Text] [Related]

  • 9. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ, Viitanen J, Lundstedt S, Ala-Opas M, Taari K, Tammela TL, FinnProstate Group.
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [Abstract] [Full Text] [Related]

  • 10. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ, Malcolm JB, Derweesh IH, Womack JH, Kincade MC, Mancini JG, Ogles ML, Lamar KD, Patterson AL, Wake RW.
    BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
    [Abstract] [Full Text] [Related]

  • 11. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.
    Spry NA, Galvão DA, Davies R, La Bianca S, Joseph D, Davidson A, Prince R.
    BJU Int; 2009 Sep; 104(6):806-12. PubMed ID: 19281463
    [Abstract] [Full Text] [Related]

  • 12. Long-term effects of intermittent androgen suppression therapy on lean and fat mass: a 33-month prospective study.
    Spry NA, Taaffe DR, England PJ, Judge JS, Stephens DA, Peddle-McIntyre C, Baker MK, Newton RU, Galvão DA.
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):67-72. PubMed ID: 22907511
    [Abstract] [Full Text] [Related]

  • 13. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB, Mottet N.
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [Abstract] [Full Text] [Related]

  • 14. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS, Pacificar JS, Shapiro CE, Williams SG.
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [Abstract] [Full Text] [Related]

  • 15. Intermittent androgen suppression--ready for prime time?
    Ischia J, Goldenberg SL.
    J Urol; 2012 Jun; 187(6):1956-7. PubMed ID: 22503023
    [No Abstract] [Full Text] [Related]

  • 16. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.
    Yoon FH, Gardner SL, Danjoux C, Morton G, Cheung P, Choo R.
    J Urol; 2008 Oct; 180(4):1438-43; discussion 1443-4. PubMed ID: 18710743
    [Abstract] [Full Text] [Related]

  • 17. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
    Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S, Canadian Uro-Oncology Group.
    J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
    [Abstract] [Full Text] [Related]

  • 18. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.
    de la Rosette J, Davis R, Frankel D, Kold Olesen T.
    Int J Clin Pract; 2011 May; 65(5):559-66. PubMed ID: 21342376
    [Abstract] [Full Text] [Related]

  • 20. A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men.
    Egawa S, Takashima R, Matsumoto K, Mizoguchi H, Kuwao S, Baba S.
    Jpn J Clin Oncol; 2000 Jan; 30(1):21-6. PubMed ID: 10770564
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.